Xynomic Pharmaceuticals Holdings, Inc. is a clinical stage biopharmaceutical company focused on in-licensing, developing and commercializing oncology drug candidates in China, US, and the rest of the world.

Xynomic Pharmaceuticals Holdings, Inc.

Juno Pharmaceuticals is a specialty pharmaceutical company that specializes in branded, complex, biosimilar and high-value generics to bring meaningful savings to the Canadian healthcare industry. It sources, develops, and delivers medications.

Juno Pharmaceuticals

2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.

2seventy bio, Inc.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Metric
Company Name	Xynomic Pharmaceuticals Holdings, Inc.	Juno Pharmaceuticals	2	AbbVie Inc.
Symbol			TSVT	ABBV
MSH ID	COM:XYNOMICPHARMA	CA:JUNOPHARM	COM:2SEVENTYBIO	COM:ABBVIE
Market	PRIVATE	PRIVATE	STOCKS	STOCKS
Sector	Healthcare & Health Services	Healthcare & Health Services	Healthcare	Healthcare
Industry	Pharmaceuticals	Pharmaceuticals	Biotechnology	Drug Manufacturers - General
Country	US	CA	US	US
Stage	Series B
Employee Count			274	50K
Website	xynomicpharma.com	junopharm.ca	2seventybio.com	abbvie.com
LinkedIn
Founders

Metric
Market Cap		197.91M	296.91B
Enterprise Value
Monthly Web Traffic	1.52K		1.18M
Web Traffic Growth	4.19		0.51
Valuation
Raised Capital			15B

Metric
Revenue	100.39M	54.32B
Revenue (LTM)
Revenue (NTM)
Gross Profit	73.18M	45.54B
EBITDA	-206.42M	18.10B
Operating Income	-216.70M	17.43B
Net Income	-217.57M	4.86B
EPS	-4.42	2.75
Diluted EPS	-4.42	2.74
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.80	0.72
Operating Profit Margin	-2.37	0.27
EBITDA Margin	-2.06	0.33
Net Profit Margin	-2.12	0.11
Return on Equity	-0.62	0.57
Return on Assets	-0.30	0.04
Return on Capital Employed	-0.44	0.15

COM:XYNOMICPHARMA

Xynomic Pharmaceuticals Holdings, Inc.

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-1.62	46.58
P/B Ratio	0.95	25.09
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	5.89	6.36
EV Multiple	0.06	17.44

Metric
Days Sales Outstanding	48.83	75.54
Days Payables Outstanding	66.57
Days Inventory Outstanding		102.41
Operating Cycle		181.71
Cash Conversion Cycle	-47.80	179.57
Asset Turnover	0.18	0.40

Metric
Operating Cash Flow	-166.86M	22.84B
Free Cash Flow	-180.72M	22.06B
Cash Flow to Debt	-0.60	0.38
Operating Cash Flow/Sales	-1.66	0.42
Free Cash Flow Yield	-0.61	0.08

Metric
Cash & Equivalents	74.96M	12.81B
Accounts Receivable		66M
Inventory	-13.41M	4.10B
Goodwill		32.29B
Debt to Capitalization	0.55	0.91
Debt to Assets	0.41	0.45
Current Ratio	4.08	0.96
Quick Ratio	5.15	0.83

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.25	0.01
R&D to Revenue	1.57	0.14
SG&A to Revenue